Hazim Aljewari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hazim Aljewari has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Wei Shi
Department of Chemistry, Ball State University, Muncie, IN 47306, USA
4 shared publications - Guanghui Zong
Department of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742, USA
3 shared publications - Christianna Stanley
NOW Diagnostics, Inc., USA
2 shared publications - Imann Mosleh
Ralph E. Martin Department of Chemical Engineering University of Arkansas Fayetteville AR 72701 USA
2 shared publications - Jody D. Berry
NOW Diagnostics
2 shared publications - Marifah Albalawi
NOW Diagnostics, Inc., USA
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by MDPI AG in Preprints.org
Control Strategies in Molecular Diagnostics: A Tiered, Risk-Based Framework for Accuracy, Reliability, and Real-World Use
Controls are fundamental to ensuring accuracy and reliability in molecular diagnostics, yet their roles are often oversimplified or conflated with broader quality assurance frameworks. As molecular testing expands from centralized laboratories to point-of-care (POC) and over the counter (OTC) settings, the design, implementation, and interpretation of controls must evolve to address diverse operational environments and clinical risks.This review introduces a comprehensive framework for understanding control strategies in molecular diagnostics, integrating internal, external, and orthogonal controls within a tiered, risk-based testing model. We categorize diagnostic systems into three tiers—screening (OTC/POC), confirmatory laboratory testing, and reference-level or adjudication testing—and examine how control requirements scale with analytical complexity, user variability, and clinical impact. Across these tiers, controls serve distinct but complementary roles, including verification of assay functionality, mitigation of contamination, maintenance of cross-platform consistency, and resolution of diagnostic uncertainty. We further analyze common failure modes in molecular diagnostics, including sample-related errors, inhibition, contamination, and interpretation challenges, and map how specific control strategies mitigate these risks. Regulatory perspectives from the U.S. Food and Drug Administration (FDA), Clinical Laboratory Improvement Amendments (CLIA), International Organization for Standardization (ISO), and World Health Organization (WHO) guidelines are discussed, highlighting the shift toward risk-based and context-dependent control design rather than rigid, one-size-fits-all requirements.Importantly, we address the balance between control burden and clinical utility, emphasizing that excessive control implementation may increase system complexity without proportionate gains in diagnostic value particularly in decentralized settings. Emerging trends, including artificial intelligence (AI)-assisted diagnostics and decentralized molecular platforms, are also explored as transformative approaches to enhancing control integration and result validation.We propose that a tier-adaptive, risk-based control framework is essential for next-generation molecular diagnostics, enabling accurate, scalable, and user-centered testing systems. This perspective supports the development of robust diagnostic platforms that maintain analytical integrity while improving accessibility and real-world performance.
- 1 May 2026
- Published by MDPI AG in Preprints.org
Open AccessControl Strategies in Molecular Diagnostics: A Tiered, Risk-Based Framework for Accuracy, Reliability, and Real-World Use
Controls are fundamental to ensuring accuracy and reliability in molecular diagnostics, yet their roles are often oversimplified or conflated with broader quality assurance frameworks. As molecular testing expands from centralized laboratories to point-of-care (POC) and over the counter (OTC) settings, the design, implementation, and interpretation of controls must evolve to address diverse operational environments and clinical risks.This review introduces a comprehensive framework for understanding control strategies in molecular diagnostics, integrating internal, external, and orthogonal controls within a tiered, risk-based testing model. We categorize diagnostic systems into three tiers—screening (OTC/POC), confirmatory laboratory testing, and reference-level or adjudication testing—and examine how control requirements scale with analytical complexity, user variability, and clinical impact. Across these tiers, controls serve distinct but complementary roles, including verification of assay functionality, mitigation of contamination, maintenance of cross-platform consistency, and resolution of diagnostic uncertainty. We further analyze common failure modes in molecular diagnostics, including sample-related errors, inhibition, contamination, and interpretation challenges, and map how specific control strategies mitigate these risks. Regulatory perspectives from the U.S. Food and Drug Administration (FDA), Clinical Laboratory Improvement Amendments (CLIA), International Organization for Standardization (ISO), and World Health Organization (WHO) guidelines are discussed, highlighting the shift toward risk-based and context-dependent control design rather than rigid, one-size-fits-all requirements.Importantly, we address the balance between control burden and clinical utility, emphasizing that excessive control implementation may increase system complexity without proportionate gains in diagnostic value particularly in decentralized settings. Emerging trends, including artificial intelligence (AI)-assisted diagnostics and decentralized molecular platforms, are also explored as transformative approaches to enhancing control integration and result validation.We propose that a tier-adaptive, risk-based control framework is essential for next-generation molecular diagnostics, enabling accurate, scalable, and user-centered testing systems. This perspective supports the development of robust diagnostic platforms that maintain analytical integrity while improving accessibility and real-world performance.
- Open Access
- 20 March 2026
- Published by MDPI AG in Preprints.org
Novel Assays and Biomarkers in Infectious Disease Detection: From Diagnosis and Prognosis to Therapeutic Monitoring and Cure Assessment
Infectious disease diagnosis remains central to clinical care, but current methods still have important limits. Clinical symptoms are often nonspecific, culture-based methods can be slow, serology depends on timing, and molecular tests may detect microbial material without always proving active disease. This review examines novel assays and biomarkers in infectious disease detection from a clinical perspective. It summarizes major diagnostic platforms, including advanced nucleic acid tests, syndromic panels, metagenomic sequencing, serological and antigen assays, point-of-care platforms, biosensors, and multi-omics approaches, and reviews pathogen-derived, host-response, and combined biomarker classes. It discusses how these tools can support diagnosis, prognosis, disease staging, therapeutic monitoring, and cure assessment. A central message is that analytical novelty alone is not enough: new assays must be accurate, timely, interpretable, and able to change patient management in real practice. Clinical symptoms and the physicians awareness of these remain critical along with the correct biomarkers. Translation is often limited by imperfect reference standards, limited external validation, poor standardization, workflow barriers, cost, and unequal access. Future priorities include stronger validation, simpler and standardized workflows, wider access through home (OTC) use, and better biomarkers for treatment response, cure, and relapse prediction.
- 20 March 2026
- Published by MDPI AG in Preprints.org
Open AccessNovel Assays and Biomarkers in Infectious Disease Detection: From Diagnosis and Prognosis to Therapeutic Monitoring and Cure Assessment
Infectious disease diagnosis remains central to clinical care, but current methods still have important limits. Clinical symptoms are often nonspecific, culture-based methods can be slow, serology depends on timing, and molecular tests may detect microbial material without always proving active disease. This review examines novel assays and biomarkers in infectious disease detection from a clinical perspective. It summarizes major diagnostic platforms, including advanced nucleic acid tests, syndromic panels, metagenomic sequencing, serological and antigen assays, point-of-care platforms, biosensors, and multi-omics approaches, and reviews pathogen-derived, host-response, and combined biomarker classes. It discusses how these tools can support diagnosis, prognosis, disease staging, therapeutic monitoring, and cure assessment. A central message is that analytical novelty alone is not enough: new assays must be accurate, timely, interpretable, and able to change patient management in real practice. Clinical symptoms and the physicians awareness of these remain critical along with the correct biomarkers. Translation is often limited by imperfect reference standards, limited external validation, poor standardization, workflow barriers, cost, and unequal access. Future priorities include stronger validation, simpler and standardized workflows, wider access through home (OTC) use, and better biomarkers for treatment response, cure, and relapse prediction.
- Open Access
Synthesis, Biological Evaluation and Docking Studies of Ring-Opened Analogues of Ipomoeassin F
The plant-derived macrocyclic resin glycoside ipomoeassin F (Ipom-F) binds to Sec61α and significantly disrupts multiple aspects of Sec61-mediated protein biogenesis at the endoplasmic reticulum, ultimately leading to cell death. However, extensive assessment of Ipom-F as a molecular tool and a therapeutic lead is hampered by its limited production scale, largely caused by intramolecular assembly of the macrocyclic ring. Here, using in vitro and/or in cellula biological assays to explore the first series of ring-opened analogues for the ipomoeassins, and indeed all resin glycosides, we provide clear evidence that macrocyclic integrity is not required for the cytotoxic inhibition of Sec61-dependent protein translocation by Ipom-F. Furthermore, our modeling suggests that open-chain analogues of Ipom-F can interact with multiple sites on the Sec61α subunit, most likely located at a previously identified binding site for mycolactone and/or the so-called lateral gate. Subsequent in silico-aided design led to the discovery of the stereochemically simplified analogue 3 as a potent, alternative lead compound that could be synthesized much more efficiently than Ipom-F and will accelerate future ipomoeassin research in chemical biology and drug discovery. Our work may also inspire further exploration of ring-opened analogues of other resin glycosides.
Open AccessSynthesis, Biological Evaluation and Docking Studies of Ring-Opened Analogues of Ipomoeassin F
The plant-derived macrocyclic resin glycoside ipomoeassin F (Ipom-F) binds to Sec61α and significantly disrupts multiple aspects of Sec61-mediated protein biogenesis at the endoplasmic reticulum, ultimately leading to cell death. However, extensive assessment of Ipom-F as a molecular tool and a therapeutic lead is hampered by its limited production scale, largely caused by intramolecular assembly of the macrocyclic ring. Here, using in vitro and/or in cellula biological assays to explore the first series of ring-opened analogues for the ipomoeassins, and indeed all resin glycosides, we provide clear evidence that macrocyclic integrity is not required for the cytotoxic inhibition of Sec61-dependent protein translocation by Ipom-F. Furthermore, our modeling suggests that open-chain analogues of Ipom-F can interact with multiple sites on the Sec61α subunit, most likely located at a previously identified binding site for mycolactone and/or the so-called lateral gate. Subsequent in silico-aided design led to the discovery of the stereochemically simplified analogue 3 as a potent, alternative lead compound that could be synthesized much more efficiently than Ipom-F and will accelerate future ipomoeassin research in chemical biology and drug discovery. Our work may also inspire further exploration of ring-opened analogues of other resin glycosides.
- Open Access
Microcystin-LR Removal from Water via Enzymatic Linearization and Ultrafiltration
Microcystin-LR (MC-LR) is a toxin produced by cyanobacteria that can bloom in freshwater supplies. This study describes a new strategy for remediation of MC-LR that combines linearization of the toxin using microcystinase A, MlrA, enzyme with rejection of linearized byproducts using membrane filtration. The MlrA enzyme was expressed in Escherichia coli (E. coli) and purified via a His-tag with 95% purity. Additionally, composite membranes made of 95% polysulfone and 5% sulfonated polyether ether ketone (SPEEK) were fabricated and used to filter a solution containing cyclic and linearized MC-LR. Tests were also performed to measure the adsorption and desorption of MC-LR on polysulfone/SPEEK membranes. Liquid chromatography-mass spectrometry (LC-MS) was used to characterize the progress of linearization and removal of MC-LR. Results indicate that the MlrA was successful at linearizing MC-LR. Membrane filtration tests showed rejection of 97% of cyclic MC-LR and virtually all linearized MC-LR, with adsorption to the membranes being the main rejection mechanism. Adsorption/desorption tests indicated that methanol could be used to strip residual MC-LR from membranes to regenerate them. This study demonstrates a novel strategy of remediation of microcystin-tainted water, combining linearization of MC-LR to a low-toxicity byproduct along with removal by membrane filtration.
Open AccessMicrocystin-LR Removal from Water via Enzymatic Linearization and Ultrafiltration
Microcystin-LR (MC-LR) is a toxin produced by cyanobacteria that can bloom in freshwater supplies. This study describes a new strategy for remediation of MC-LR that combines linearization of the toxin using microcystinase A, MlrA, enzyme with rejection of linearized byproducts using membrane filtration. The MlrA enzyme was expressed in Escherichia coli (E. coli) and purified via a His-tag with 95% purity. Additionally, composite membranes made of 95% polysulfone and 5% sulfonated polyether ether ketone (SPEEK) were fabricated and used to filter a solution containing cyclic and linearized MC-LR. Tests were also performed to measure the adsorption and desorption of MC-LR on polysulfone/SPEEK membranes. Liquid chromatography-mass spectrometry (LC-MS) was used to characterize the progress of linearization and removal of MC-LR. Results indicate that the MlrA was successful at linearizing MC-LR. Membrane filtration tests showed rejection of 97% of cyclic MC-LR and virtually all linearized MC-LR, with adsorption to the membranes being the main rejection mechanism. Adsorption/desorption tests indicated that methanol could be used to strip residual MC-LR from membranes to regenerate them. This study demonstrates a novel strategy of remediation of microcystin-tainted water, combining linearization of MC-LR to a low-toxicity byproduct along with removal by membrane filtration.
- Open Access
- 3 March 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Biology-directed and in silico-aided design liberates a potent, simplified and ipomoeassin-F-derived Sec61 inhibitor
The macrocyclic small molecule inhibitor ipomoeassin F (Ipom-F) binds to the central Sec61α subunit of the Sec61 complex and induces cytotoxicity by disrupting multiple aspects of Sec61-mediated protein biogenesis at the endoplasmic reticulum (ER). Here, we show that the integrity of the Ipom-F macrocycle is not required either for Sec61 inhibition in vitro or the induction of cell death, which is abrogated in cells expressing a resistance-conferring Sec61α mutant. We conclude that Ipom-F and its open-chain analogues interact with Sec61α via its mycolactone binding site and/or lateral gate, thereby occluding the normal Sec61-mediated pathway for membrane protein insertion at the ER. Using biology-directed and in silico-aided design, we have revolutionised the production of Ipom-F to yield open-chain analogue 3; a potent, simplified and synthetically accessible Ipom-F-derived Sec61 inhibitor. We present 3 as a lead compound for the generation of new protein translocation probes and future therapeutic development.
- 3 March 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBiology-directed and in silico-aided design liberates a potent, simplified and ipomoeassin-F-derived Sec61 inhibitor
The macrocyclic small molecule inhibitor ipomoeassin F (Ipom-F) binds to the central Sec61α subunit of the Sec61 complex and induces cytotoxicity by disrupting multiple aspects of Sec61-mediated protein biogenesis at the endoplasmic reticulum (ER). Here, we show that the integrity of the Ipom-F macrocycle is not required either for Sec61 inhibition in vitro or the induction of cell death, which is abrogated in cells expressing a resistance-conferring Sec61α mutant. We conclude that Ipom-F and its open-chain analogues interact with Sec61α via its mycolactone binding site and/or lateral gate, thereby occluding the normal Sec61-mediated pathway for membrane protein insertion at the ER. Using biology-directed and in silico-aided design, we have revolutionised the production of Ipom-F to yield open-chain analogue 3; a potent, simplified and synthetically accessible Ipom-F-derived Sec61 inhibitor. We present 3 as a lead compound for the generation of new protein translocation probes and future therapeutic development.
- 15 July 2021
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 13 (29) , 35019-35025
Cationic Covalent Organic Framework as an Ion Exchange Material for Efficient Adsorptive Separation of Biomolecules
Although covalent organic frameworks (COFs) have earned significant interest in separation applications, the use of COFs in biomolecule separation remains unexplored. We examined the ionic COF Py-BPy2+–COF as an ion exchange material for biomolecule separation. After characterizing the properties of the synthesized COF with a variety of techniques, binding experiments with both large and small biomolecules were performed. High adsorption capacities of amino acids with different hydrophobicity and charge, as well as proteins of different isoelectric points and molecular weights, were determined in batch equilibrium experiments. Desorption experiments with mixtures of model proteins demonstrated an ability to successfully separate one protein from another with the selectivity hypothesized to be a combination of the isoelectric point, hydrophobicity, and ability to penetrate the crystalline material. Overall, the results demonstrated that Py-BPy2+–COF can be exploited as a robust crystalline anion exchange biomolecule separation material.
- 15 July 2021
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 13 (29) , 35019-35025
Cationic Covalent Organic Framework as an Ion Exchange Material for Efficient Adsorptive Separation of Biomolecules
Although covalent organic frameworks (COFs) have earned significant interest in separation applications, the use of COFs in biomolecule separation remains unexplored. We examined the ionic COF Py-BPy2+–COF as an ion exchange material for biomolecule separation. After characterizing the properties of the synthesized COF with a variety of techniques, binding experiments with both large and small biomolecules were performed. High adsorption capacities of amino acids with different hydrophobicity and charge, as well as proteins of different isoelectric points and molecular weights, were determined in batch equilibrium experiments. Desorption experiments with mixtures of model proteins demonstrated an ability to successfully separate one protein from another with the selectivity hypothesized to be a combination of the isoelectric point, hydrophobicity, and ability to penetrate the crystalline material. Overall, the results demonstrated that Py-BPy2+–COF can be exploited as a robust crystalline anion exchange biomolecule separation material.
- 2 January 2020
- Published by Wiley in Biotechnology Progress
- Vol. 36 (3) , e2956
Recombinant peptide fusion construction for protein‐templated catalytic palladium nanoparticles
Although peptide‐enabled synthesis of nanostructures has garnered considerable interest for use in catalytic applications, it has so far been achieved mostly via Fmoc based solid phase peptide synthesis. Consequently, the potential of longer peptides in nanoparticle synthesis have not been explored largely due to the complexities and economic constraints of this chemical synthesis route. This study examines the potential of a 45‐amino acid long peptide expressed as fusion to green fluorescence protein (GFPuv) in Escherichia coli for use in palladium nanoparticle synthesis. Fed‐batch fermentation with E . coli harboring an arabinose‐inducible plasmid produced a product containing three copies of Pd4 peptide fused to N‐terminus of GFPuv ((Pd4) 3 ‐GFPuv). Using the intrinsic fluorescence of GFPuv, expression and enrichment of the fusion product was easily monitored. Crude lysate, desalted lysate, and an ion‐exchange enriched fraction containing (Pd4) 3 ‐GFPuv were used to test the hypothesis that high purity of the biologic material used as the nanoparticle synthesis template may not be necessary. Nanoparticles were characterized using a variety of material science techniques and used to catalyze a model Suzuki–Miyaura coupling reaction. Results demonstrated that palladium nanoparticles can be synthesized using the soluble cell extract containing (Pd4) 3 ‐GFPuv without extensive purification or cleavage steps, and as a catalyst the crude mixture is functional.
- 2 January 2020
- Published by Wiley in Biotechnology Progress
- Vol. 36 (3) , e2956
Recombinant peptide fusion construction for protein‐templated catalytic palladium nanoparticles
Although peptide‐enabled synthesis of nanostructures has garnered considerable interest for use in catalytic applications, it has so far been achieved mostly via Fmoc based solid phase peptide synthesis. Consequently, the potential of longer peptides in nanoparticle synthesis have not been explored largely due to the complexities and economic constraints of this chemical synthesis route. This study examines the potential of a 45‐amino acid long peptide expressed as fusion to green fluorescence protein (GFPuv) in Escherichia coli for use in palladium nanoparticle synthesis. Fed‐batch fermentation with E . coli harboring an arabinose‐inducible plasmid produced a product containing three copies of Pd4 peptide fused to N‐terminus of GFPuv ((Pd4) 3 ‐GFPuv). Using the intrinsic fluorescence of GFPuv, expression and enrichment of the fusion product was easily monitored. Crude lysate, desalted lysate, and an ion‐exchange enriched fraction containing (Pd4) 3 ‐GFPuv were used to test the hypothesis that high purity of the biologic material used as the nanoparticle synthesis template may not be necessary. Nanoparticles were characterized using a variety of material science techniques and used to catalyze a model Suzuki–Miyaura coupling reaction. Results demonstrated that palladium nanoparticles can be synthesized using the soluble cell extract containing (Pd4) 3 ‐GFPuv without extensive purification or cleavage steps, and as a catalyst the crude mixture is functional.
- 21 March 2016
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 18 (7) , 1674-1677
Revealing the Pharmacophore of Ipomoeassin F through Molecular Editing
Ipomoeassin F, the flagship congener of a resin glycoside family exhibited single-digit nanomolar IC50 values against several cancer cell lines. To facilitate drug discovery based on this unique yet underexplored natural product, we performed the most sophisticated SAR studies of ipomoeassin F to date, which not only greatly bettered our understanding of its pharmacophore but also led to the discovery of two new derivatives (3 and 27) with similar potency but improved synthetic profile. The work presented here opens new avenues toward harnessing the medicinal potential of the ipomoeassin family of glycolipids in the future.
- 21 March 2016
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 18 (7) , 1674-1677
Revealing the Pharmacophore of Ipomoeassin F through Molecular Editing
Ipomoeassin F, the flagship congener of a resin glycoside family exhibited single-digit nanomolar IC50 values against several cancer cell lines. To facilitate drug discovery based on this unique yet underexplored natural product, we performed the most sophisticated SAR studies of ipomoeassin F to date, which not only greatly bettered our understanding of its pharmacophore but also led to the discovery of two new derivatives (3 and 27) with similar potency but improved synthetic profile. The work presented here opens new avenues toward harnessing the medicinal potential of the ipomoeassin family of glycolipids in the future.
- 28 August 2015
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 80 (18) , 9279-9291
Total Synthesis and Biological Evaluation of Ipomoeassin F and Its Unnatural 11R-Epimer
Ipomoeassin F, a macrolide glycoresin containing an embedded disaccharide, possesses potent in vitro antitumor activity with an unknown mechanism of function. It inhibits tumor cell growth with single-digit nanomolar IC50 values, superior to many clinical chemotherapeutic drugs. To facilitate translation of its bioactivity into protein function for drug development, we report here a new synthesis for the gram-scale production of ipomoeassin F (3.8% over 17 linear steps) from commercially available starting materials. The conformation-controlled subtle reactivity differences of the hydroxyl groups in carbohydrates were utilized to quickly construct the disaccharide core, which, along with judicial selection of protecting groups, made the current synthesis very efficient. The same strategy was also applied to the smooth preparation of the 11R-epimer of ipomoeassin F for the first time. Cytotoxicity assays demonstrated the crucial role of the natural 11S configuration. In addition, cell cycle analyses and apoptosis assays on ipomoeassin F and/or its epimer were conducted. This work has laid a solid foundation for understanding the medicinal potential of the ipomoeassin family of glycolipids in the future.
- 28 August 2015
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 80 (18) , 9279-9291
Total Synthesis and Biological Evaluation of Ipomoeassin F and Its Unnatural 11R-Epimer
Ipomoeassin F, a macrolide glycoresin containing an embedded disaccharide, possesses potent in vitro antitumor activity with an unknown mechanism of function. It inhibits tumor cell growth with single-digit nanomolar IC50 values, superior to many clinical chemotherapeutic drugs. To facilitate translation of its bioactivity into protein function for drug development, we report here a new synthesis for the gram-scale production of ipomoeassin F (3.8% over 17 linear steps) from commercially available starting materials. The conformation-controlled subtle reactivity differences of the hydroxyl groups in carbohydrates were utilized to quickly construct the disaccharide core, which, along with judicial selection of protecting groups, made the current synthesis very efficient. The same strategy was also applied to the smooth preparation of the 11R-epimer of ipomoeassin F for the first time. Cytotoxicity assays demonstrated the crucial role of the natural 11S configuration. In addition, cell cycle analyses and apoptosis assays on ipomoeassin F and/or its epimer were conducted. This work has laid a solid foundation for understanding the medicinal potential of the ipomoeassin family of glycolipids in the future.